# Pro Dex Inc: Form 10-Q for the period ended Mar 31, 2023

- Company: [Pro Dex Inc](/companies/pdex.md) (CIK 788920)
- Form: 10-Q
- Filed: 2023-05-04
- Accepted by EDGAR: May 4, 2023, 16:00 ET
- Period: 2023-03-31
- Accession: 0001553350-23-000285
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/788920/000155335023000285/pdex_10q-033123.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/788920/000155335023000285/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $13.1m | us-gaap:Revenues |
| Revenue | 9 months, 2022-07-01 to 2023-03-31 | $35.4m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $9.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2022-07-01 to 2023-03-31 | $26.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $3.8m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-07-01 to 2023-03-31 | $9.4m | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-01-01 to 2023-03-31 | $713.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2022-07-01 to 2023-03-31 | $2.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | $2.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-07-01 to 2023-03-31 | $4.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-01-01 to 2023-03-31 | $131.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2022-07-01 to 2023-03-31 | $389.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | $455.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-07-01 to 2023-03-31 | $968.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | $1.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-07-01 to 2023-03-31 | $3.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.36 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-07-01 to 2023-03-31 | $0.89 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-07-01 to 2023-03-31 | $0.91 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 3,623,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-07-01 to 2023-03-31 | 3,656,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-07-01 to 2023-03-31 | $4.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-07-01 to 2023-03-31 | $822.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2022-07-01 to 2023-03-31 | $1.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2023-03-31 | $2.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $31.1m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $47.0m | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $10.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $21.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-03-31 | $25.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 34,300 characters.

*The following discussion and analysis should be read in conjunction with our unaudited interim condensed financial statements and the related notes and other financial information appearing elsewhere in this report.*

COMPANY OVERVIEW

The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of the results of operations and financial condition of Pro-Dex, Inc. (“Company,” “Pro-Dex,” “we,” “our,” or “us”) for the three-month and nine-month periods ended March 31, 2023 and 2022. This discussion should be read in conjunction with the condensed financial statements and the notes thereto included elsewhere in this report. This report contains certain forward-looking statements and information. The cautionary statements included herein should be read as being applicable to all related forward-looking statements wherever they may appear. Our actual future results could differ materially from those discussed herein.

Except for the historical information contained herein, the matters discussed in this report, including, but not limited to, discussions of our product development plans, business strategies, strategic opportunities and market factors influencing our results, including uncertainties related to the COVID-19 pandemic, are forward-looking statements that involve certain risks and uncertainties. Actual results may differ from those anticipated by us as a result of various factors, both foreseen and unforeseen, including, but not limited to, our ability to continue to develop new products and increase sales in markets characterized by rapid technological evolution, the impact of the COVID-19 pandemic on our suppliers, customers, and us, consolidation within our target marketplace and among our competitors, competition from larger, better capitalized competitors, and our ability to realize returns on opportunities. Many other economic, competitive, governmental, and technological factors could impact our ability to achieve our goals. You are urged to review the risks, uncertainties, and other cautionary language described in this report, as well as in our other public disclosures and reports filed with the Securities and Exchange Commission (“SEC”) from time to time, including, but not limited to, the risks, uncertainties, and other cautionary language discussed in our Annual Report on Form 10-K for our fiscal year ended June 30, 2022.

We specialize in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial (“CMF”) markets. We have patented adaptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. We also manufacture and sell rotary air motors to a wide range of industries.

Our principal headquarters are located at 2361 McGaw Avenue, Irvine, California 92614 and our phone number is (949) 769-3200. Our Internet address is www.pro-dex.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, amendments to those reports and other SEC filings are available free of charge through our website as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. In addition, our Code of Ethics and other corporate governance documents may be found on our website at the Internet address set forth above. Our filings with the SEC may also be read and copied at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov and company specific information at www.sec.gov/edgar/searchedgar/companysearch.html.

Basis of Presentation

The condensed consolidated results of operations presented in this report are not audited and those results are not necessarily indicative of the results to be expected for the entirety of the fiscal year ending June 30, 2023. Our fiscal year ends on June 30 and our fiscal quarters end on September 30, December 31, and March 31. Unless otherwise stated, all dates refer to our fiscal year and those fiscal quarters.

Critical Accounting Estimates and Judgments

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used or changes in the accounting estimate that are reasonably likely to occur could materially change the financial statements. Management believes that there have been no significant changes during the three and nine months ended March 31, 2023 to the items that we disclosed as our critical accounting policies in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022.

Business Strategy and Future Plans

Our business today is almost entirely driven by sales of our medical devices. Many of our significant customers place purchase orders for specific products that were developed under various development and/or supply agreements. Our customers may request that we design and manufacture a custom surgical device or they may hire us as a contract manufacturer to manufacture a product of their own design. In either case, we have extensive experience with autoclavable, battery-powered and electric, multi-function surgical drivers and shavers. We continue to focus a significant percentage of our time and resources on providing outstanding products and service to our valued principal customers. During the first quarter of fiscal 2021, our largest customer executed an amendment to our existing supply agreement such that we shall continue to supply their surgical handpieces to them through calendar 2025.

Simultaneously, we are working to build top-line sales through active proposals of new medical device products with new and existing customers. Our patented adaptive torque-limiting software has been very well received in the CMF and thoracic markets. Additionally, we have other significant engineering projects under way described more fully below under “Results of Operations.”

In November 2020, we purchased an approximate 25,000 square foot industrial building in Tustin, California (the “Franklin Property”). This building is located approximately four miles from our Irvine, California headquarters and was acquired to provide us additional capacity for our expected continued future growth, including anticipated expanded capacity for the manufacture of batteries and new products. We substantially completed the build-out of the property in the first quarter of the prior fiscal year. Currently, we are actively engaged in various verification and validation activities and we expect we will begin operations in the new facility during the fourth quarter of this fiscal year.

In summary, our current objectives are focused primarily on maintaining our relationships with our current medical device customers, expanding our manufacturing capacity with the addition of the Franklin Property, investing in research and development activities to design Pro-Dex branded drivers to leverage our torque-limiting software, and promoting active product development proposals to new and existing customers for orthopedic shavers, screw drivers for a multitude of surgical applications, and other medical devices, while monitoring closely the progress of all these individual endeavors. Our investments in research and development have historically increased disproportionately to our growth in revenue and we anticipate this may continue in future periods. These expenditures are being made in an effort to release new products and garner new customer relationships. This fiscal year, however, the majority of our engineering efforts relate to customer funded non-recurring engineering (“NRE”) projects, which costs are reclassified to cost of sales. While we expect revenue growth in the future, it may not be a consistent trajectory but rather periods of incremental growth that current expenditures are helping to create. However, there can be no assurance that we will be successful in any of these objectives.

COVID-19 Pandemic

We have adjusted certain policies and procedures based on applicable national, state, and local emergency orders and safety guidance that may be issued from time to time, in order to effectively manage our business during the pandemic and to keep our employees safe. These measures have changed over time and continue to change as our specific circumstances change.

While we have yet to see any significant decline in our customer orders, we have received and accepted some customer requests to delay the shipment of their existing orders. We are focused on the health and safety of all those we serve – our customers, our communities, our employees, and our suppliers. We are supporting our customers according to their priorities and working with them to the degree that we can offer relief in the form of delayed shipments. We are focused on continuity of supply by working with our suppliers, some of whom have delivered our orders late and are quoting longer lead times.

During fiscal 2022, we began to see some challenges in our supply chain in the form of delayed shipments, longer lead times, higher prices, and surcharges, much of which our suppliers indicate have been caused by the COVID-19 pandemic. We have largely been able to mitigate our biggest supply chain concerns by sourcing replacement chips through alternative suppliers, albeit at much higher prices, for many of our printed circuit board assemblies. In so doing, our cost of sales increased during the second half of fiscal 2022 and thus far in fiscal 2023. We continue to implement plans and processes to mitigate these challenges that many manufacturers similarly face. Our long-term prospects remain positive, and we believe these challenges will negatively impact us only in the short-term.

Description of Business Operations

### Revenue

The majority of our revenue is derived from designing, developing and manufacturing surgical devices for the medical device industry. The proportion of total sales by type is as follows (in thousands, except percentages):

| Net Sales: | Three Months Ended March 31, 2023 | % of Revenue | 2022 | % of Revenue | Nine Months Ended March 31, 2023 | % of Revenue | 2022 | % of Revenue |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Medical device products | 6,990 | 54% | 6,527 | 70% | 23,631 | 67% | 23,199 | 79% |
| Industrial and scientific | 260 | 2% | 321 | 4% | 691 | 2% | 775 | 3% |
| Dental and component | 43 | — | 203 | 2% | 182 | — | 348 | 1% |
| NRE & Proto-type | 970 | 7% | 549 | 6% | 2,361 | 7% | 859 | 3% |
| Repairs and other | 4,816 | 37% | 1,665 | 18% | 8,583 | 24% | 4,245 | 14% |
|  | 13,079 | 100% | 9,265 | 100% | 35,448 | 100% | 29,426 | 100% |

Certain of our medical device products utilize proprietary designs developed by us under exclusive development and supply agreements. All of our medical device products utilize proprietary manufacturing methods and know-how, and are manufactured in our Irvine, California facility, as are our industrial products. Details of our medical device sales by type is as follows (in thousands, except percentages):

| Medical device sales: | Three Months Ended March 31, 2023 | % of Total | 2022 | % of Total | Nine Months Ended March 31, 2023 | % of Total | 2022 | % of Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Orthopedic | 3,866 | 55% | 3,233 | 50% | 15,271 | 65% | 14,270 | 62% |
| CMF | 2,886 | 41% | 2,093 | 32% | 7,208 | 30% | 7,084 | 30% |
| Thoracic | 238 | 4% | 1,201 | 18% | 1,152 | 5% | 1,845 | 8% |
| Total | 6,990 | 100% | 6,527 | 100% | 23,631 | 100% | 23,199 | 100% |

Sales of our medical device products increased $463,000, or 7%, and $432,000, or 2%, respectively, for the three and nine months ended March 31, 2023, compared to the corresponding periods of the prior fiscal year. Our medical device revenue to our largest customer, included in orthopedic sales above, increased $633,000 and $1.0 million, respectively, for the three and nine months ended March 31, 2023 compared to the corresponding periods of the prior fiscal year. Additionally, recurring revenue from distributors of CMF drivers increased $793,000 and $124,000, respectively, for the three and nine months ended March 31, 2023, compared to the corresponding periods of the prior fiscal year in part due to the launch of a new driver to our existing largest customer during the third quarter of the prior fiscal year. Our thoracic sales revenue decreased $963,000 and $693,000, for the three and nine months ended March 31, 2023, respectively, compared to the corresponding periods of the prior fiscal year, due primarily as a result of our customer for our thoracic driver filling the near-term requirements of its distribution network.

Sales of our compact pneumatic air motors, reported as industrial and scientific sales above, decreased $61,000, or 19%, and $84,000, or 11%, respectively, for the three and nine months ended March 31, 2023, compared to the corresponding periods of the prior fiscal year. These are legacy products with no substantive marketing efforts. Our NRE and proto-type revenue increased $421,000, or 77%, and $1.5 million, or 175%, for the three and nine months ended March 31, 2023, compared to the corresponding periods of the prior fiscal year, due to an increase in billable contracts for various NRE projects undertaken for our customers.

Sales of our dental products and components decreased $160,000, or 79%, and $166,000, or 48%, respectively, for the three and nine months ended March 31, 2023, compared to the corresponding periods of the prior fiscal year. In the prior fiscal year we sold component inventory to our largest customer used in their legacy design which did not recur in the current fiscal year. We expect future declines in this area as we are no longer manufacturing dental products, but rather are simply selling remaining component inventory.

Repair revenue increased $3.2 million or 189%, and $4.3 million, or 102%, for the three and nine months ended March 31, 2023, respectively, compared to the corresponding periods of the prior fiscal year due to increased repairs of the orthopedic handpiece we sell to our largest customer. This increase was expected as we have been upgrading handpieces to the next generation, which design was released to manufacture in the third quarter of fiscal 2022. Additionally, we completed negotiations on repair pricing and terms with this customer during the three months ended March 31, 2023, and received an additional $520,000 in compensation during the third quarter of this fiscal year, for handpieces upgraded between July 2022 and December 2022 and reached an agreement for future consideration which we expect to recognize in a future fiscal year. We expect to continue to see increases in repair revenue, albeit at reduced margins, for the remainder of this fiscal year because this customer has requested that we perform an enhanced repair on each handpiece, which includes the advance replacement of certain components.

At March 31, 2023, we had a backlog of approximately $18.8 million, of which $8.5 million is scheduled to be delivered in the fourth quarter of fiscal 2023 and the balance is scheduled to be delivered next fiscal year and beyond. Our backlog represents firm purchase orders received and acknowledged from our customers and does not include all revenue expected to be generated from existing customer contracts. We may experience variability in our new order bookings due to various reasons, including, but not limited to, the timing of major new product launches and customer planned inventory builds. However, we do not typically experience seasonal fluctuations in our shipments and revenues.

### Cost of Sales and Gross Margin

### (in thousands except percentages)

| Cost of sales: | Three Months Ended March 31, 2023 | % of Total | 2022 | % of Total | Nine Months Ended March 31, 2023 | % of Total | 2022 | % of Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Product cost | 8,510 | 92% | 5,465 | 85% | 24,066 | 92% | 18,436 | 94% |
| Under(over)-absorption of manufacturing costs | 729 | 8% | 528 | 8% | 1,705 | 7% | 631 | 3% |
| Inventory and warranty charges | 29 | — | 414 | 7% | 287 | 1% | 670 | 3% |
| Total cost of sales | 9,268 | 100% | 6,407 | 100% | 26,058 | 100% | 19,737 | 100% |

|  | Three Months Ended March 31, 2023 | 2022 | Nine Months Ended March 31, 2023 | 2022 | Year over Year ppt Change Three Months | Nine Months |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Gross margin | 29% | 31% | 26% | 33% | (2) | (7) |

Cost of sales for the three months ended March 31, 2023, increased $2.9 million, or 45%, compared to the corresponding period of the prior fiscal year. The increase in total costs of sales was caused by the 41% increase in revenue for the same period. Under-absorption of manufacturing costs increased by $201,000 for the three months ended March 31, 2023, compared to the corresponding period of the prior fiscal year due in part to our inability to absorb our fixed costs, which were not reduced in the third quarter of the current fiscal year in anticipation of future revenue growth. Costs relating to inventory and warranty charges decreased $385,000 for the third quarter ended March 31, 2023 compared to the third quarter of the prior fiscal year, largely due to a reduction in warranty expenses.

Gross profit increased by approximately $953,000, or 33%, for the three months ended March 31, 2023, compared to the corresponding period of the prior fiscal year, consistent with the overall increase in revenue. Gross margin as a percentage of sales decreased by approximately 2 percentage points compared to the corresponding period of the prior fiscal year due primarily to increased under-absorption of manufacturing costs as a result of additional indirect costs in our manufacturing, assembly, and quality departments, especially related to ongoing verification and validation activities for the Franklin Property.

Cost of sales for the nine months ended March 31, 2023 increased by $6.3 million, or 32%, compared to the corresponding period of the prior fiscal year. Although some of the increase in cost of sales is consistent with the 21% increase in revenue for the same period, the reasons for which are discussed above, the enhanced repair program implemented for our largest customer includes the advance replacement of certain components which has contributed to a $1.4 million increase in cost of sales. Additionally, total cost of sales reflects a $1.1 million increase in under-absorbed manufacturing costs due to actual production hours being less than planned as well as the additional indirect costs in our manufacturing, assembly, and quality operations described above. Inventory and warranty charges decreased by approximately $383,000, or 57%, for the nine months ended March 31, 2023, compared to the corresponding period of the prior fiscal year, due to reduced component inventory write-downs as a result of sourcing high priced components for our printed circuit board assemblies in the prior fiscal year.

Gross profit decreased by $299,000, or 3%, for the nine months ended March 31, 2023, compared to the corresponding period of the prior fiscal year, primarily as a result of the increase in cost of sales described above. Gross margin for the nine months ended March 31, 2023, decreased by 7 percentage points compared to the corresponding period of the prior fiscal year.

### Operating Expenses

### Operating Costs and Expenses

### (in thousands except percentages)

| Operating expenses: | Three Months Ended March 31, 2023 | % of Net Sales | 2022 | % of Net Sales | Nine Months Ended March 31, 2023 | % of Net Sales | 2022 | % of Net Sales | Year over Year % Change Three Months | Nine Months |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling expenses | 24 | — | 20 | — | 146 | — | 79 | — | 20% | 85% |
| General and administrative expenses | 1,009 | 8% | 1,145 | 13% | 2,983 | 9% | 3,402 | 12% | (12%) | (12%) |
| Research and development costs | 713 | 5% | 658 | 7% | 2,109 | 6% | 2,254 | 8% | 8% | (6%) |
|  | 1,746 | 13% | 1,823 | 20% | 5,238 | 15% | 5,735 | 20% | (4%) | (9%) |

Selling expenses consist of salaries and other personnel-related expenses for our business development department, as well as advertising and marketing expenses, and travel and related costs incurred in generating and maintaining our customer relationships. Selling expenses for the three and nine months ended March 31, 2023, increased $4,000, or 20%, and $67,000, or 85%, respectively, compared to the corresponding periods of fiscal 2022. The increase is primarily due to increased sales commissions.

General and administrative expenses (“G&A”) consist of salaries and other personnel-related expenses of our accounting, finance and human resource personnel, as well as costs for outsourced information technology services, professional fees, directors’ fees, and other costs and expenses attributable to being a public company. G&A decreased $136,000 and $419,000, respectively, during the three and nine months ended March 31, 2023, when compared to the corresponding periods of the prior fiscal year. The decreases relate primarily to reduced legal and settlement expenses related to employment matters and reduced non-cash compensation expense related to stock compensation, offset by increased legal fees related to intellectual property matters.

Research and development costs generally consist of salaries, employer-paid benefits, and other personnel- related costs of our engineering and support personnel, as well as allocated facility and information technology costs, professional and consulting fees, patent-related fees, lab costs, materials, and travel and related costs incurred in the development and support of our products. Research and development costs for the three months ended March 31, 2023, increased $55,000, or 8%, compared to the corresponding periods of the prior fiscal year. Research and development costs for the nine months ended March 31, 2023, decreased $145,000, or 6%, compared to the corresponding periods of the prior fiscal year. This relates to increased personnel and related expense offset by decreased spending on internal engineering projects and a shift to increased spending on billable development projects. When our engineers are engaged in a billable project as opposed to an internal project, costs get shifted to cost of sales instead of research and development.

Although the majority of our research and development costs relate to sustaining activities related to products we currently manufacture and sell, we have created a product roadmap to develop future products. Many of our product development efforts are undertaken only upon completion of an analysis of the size of the market, our ability to differentiate our product from our competitors’, as well as an analysis of our specific sales prospects with new and/or existing customers. The research and development costs represent between 36% and 41% of total operating expenses for all periods presented and are expected to increase in the future as we continue to invest in product development efforts. The amount spent on internal projects under development is summarized below (in thousands):

|  | Three and Nine Months Ended March 31, 2023 |  | Three and Nine Months Ended March 31, 2022 |  | Market Launch (1) | Est Annual Revenue (2) |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| Total Research & Development costs: | $713 | $2,109 | $658 | $2,254 |  |  |
| Products in development: |  |  |  |  |  |  |
| ENT Shaver | 6 | 50 | 15 | 278 | Q4 2023 | $1,000 |
| Sustaining & Other | 707 | 2,059 | 643 | 1,976 |  |  |
| Total. | $713 | $2,109 | $658 | $2,254 |  |  |

(1) Represents the calendar quarter of expected market launch.

(2) The products in development include risks that they could be abandoned in the future prior to completion, they could fail to become commercialized, or the actual annual revenue realized may be less than the amount estimated.

As we introduce new products into the market, we expect to see an increase in sustaining and other engineering expenses. Typical examples of sustaining engineering activities include, but are not limited to, end-of- life component replacement, especially in electronic components found in our printed circuit board assemblies, analysis of customer complaint data to improve process and design, replacement and enhancement of tooling and fixtures used in our machine shop, assembly operations, and inspection areas to improve efficiency and through-put. Additionally, these costs include development projects that may be in their infancy and may or may not result in a full-fledged product development effort.

### Interest & Other Income

Interest income for the three and nine months ended March 31, 2023 and 2022, includes interest and dividends from our money market accounts and investment portfolio.

### Interest Expense

Interest expense consists primarily of interest expense related to the notes payable described more fully in Note 10 to the condensed consolidated financial statements contained elsewhere in this report.

### Unrealized gain (loss) on marketable equity investments

The unrealized gain (loss) on marketable equity investments relates to our investment portfolio more fully described in Note 4 to the condensed consolidated financial statements contained elsewhere in this report.

### Gain on Sale of Investments

During the first quarter ended September 30, 2022, we sold some of the stocks in our portfolio of equity investments receiving proceeds of $88,000 and recording a gain on the sale in the amount of $7,000.

### Income Tax Expense

The effective tax rate for the three and nine months ended March 31, 2023 and 2022, is slightly less than our combined expected federal and applicable state corporate income tax rates due to federal and state research credits. Additionally, the current year effective tax rate for the nine months ended March 31, 2023 is less than our combined expected federal and applicable state corporate income tax rates due to a tax benefit recognized as a result of common stock awarded to employees under previously granted performance awards in the first quarter of fiscal 2023 as described more fully in Note 8 to the condensed consolidated financial statements contained elsewhere in this report, as well as unrealized gains on our marketable equity investments.

### Liquidity and Capital Resources

Cash and cash equivalents at March 31, 2023, increased $1.2 million to $2.1 million as compared to $849,000 at June 30, 2022. The following table includes a summary of our condensed statements of cash flows contained elsewhere in this report.

*(in thousands)*

| Cash provided by (used in): | As of and For the Nine Months Ended March 31, 2023 | 2022 |
| --- | ---: | ---: |
| Operating activities | $4,835 | $4,432 |
| Investing activities | $(733) | $(1,636) |
| Financing activities | $(2,863) | $(1,756) |
| Cash and Working Capital: |  |  |
| Cash and cash equivalents | $2,088 | $4,761 |
| Working capital | $21,001 | $20,376 |

Operating Activities

Net cash provided by operating activities was $4.8 million for the nine months ended March 31, 2023, primarily due to net income of $3.3 million, non-cash depreciation and amortization of $594,000, share-based compensation of $584,000, and collections of accounts receivable in the amount of $4.8 million offset by a decrease in accounts payable and accrued expenses of $1.0 million, a decrease in deferred revenue of $956,000, and an increase in inventory in the amount of $2.5 million.

Net cash provided by operating activities was $4.4 million for the nine months ended March 31, 2022, primarily due to net income of $2.4 million, non-cash depreciation and amortization of $546,000, share-based compensation of $932,000 and unrealized losses on marketable securities in the amount of $427,000, as well as an increase in accounts payable and accrued expenses of $673,000, an increase in deferred revenue of $746,000, and a decrease in accounts receivable in the amount of $2.3 million. Offsetting these sources of cash, our inventory increased by $3.4 million primarily due to replenishment of sub-assemblies and long-lead time parts.

Investing Activities

Net cash used in investing activities for the nine months ended March 31, 2023, was $733,000 and related primarily to the purchases of equipment and improvements primarily for the Franklin Property totaling $822,000. Offsetting this use of cash, we sold some of our marketable securities during the nine months ended March 31, 2023 for $89,000.

Net cash used in investing activities for the nine months ended March 31, 2022, was $1.6 million and related to purchases of equipment and improvements primarily for the Franklin Property in the amount of $1.3 million and investments in marketable equity securities of publicly traded companies in the amount of $334,000.

Financing Activities

Net cash used in financing activities for the nine months ended March 31, 2023, totaled $2.9 million and related primarily to the $1.5 million repurchase of 86,422 shares of our common stock pursuant to our share repurchase program, $4.8 million of payments to Minnesota Bank and Trust (“MBT”) as well as payment of $223,000 of employee payroll taxes related to the award of 37,500 shares of common stock to employees under previously granted performance awards. Offsetting these uses of cash we also borrowed $3.6 million from MBT under our amended revolving loan, and collected $78,000 and $11,000, respectively, related to employee contributions to the ESPP plan and exercises of stock options.

Net cash used in financing activities for the nine months ended March 31, 2022, totaled $1.8 million and related primarily to the $1.3 million repurchase of 52,718 shares of our common stock pursuant to our share repurchase program as well as $561,000 of principal payments on our loans from MBT more fully described in Note 10 to the condensed consolidated financial statements contained elsewhere in this report.

Financing Facilities & Liquidity Requirements for the next twelve months

As of March 31, 2023, our working capital was $21.0 million. We currently believe that our existing cash and cash equivalent balances together with our accounts receivable balances will provide us sufficient funds to satisfy our cash requirements as our business is currently conducted for at least the next 12 months. In addition to our cash and cash equivalent balances, we expect to derive a portion of our liquidity from our cash flows from operations. We may also liquidate some or all of our investment portfolio or borrow further against our $7.0 million Amended Revolving Loan with MBT (see Note 10 to condensed consolidated financial statements contained elsewhere in this report), under which we had availability of $5.2 million as of March 31, 2023.

We are focused on preserving our cash balances by monitoring expenses, identifying cost savings, and investing only in those development programs and products that we believe will most likely contribute to our profitability. As we execute on our current strategy, however, we may require debt and/or equity capital to fund our working capital needs and requirements for capital equipment to support our manufacturing and inspection processes. In particular, we have experienced negative operating cash flow in the past, especially as we procure long-lead time materials to satisfy our backlog, which can be subject to extensive variability. We believe that if we need to raise additional capital to fund our operations beyond the cash available from the strategies mentioned above, we can do so by selling additional shares of our common stock under the ATM Agreement. (See Note 11 to condensed consolidated financial statements contained elsewhere in this report).

Investment Strategy

We invest surplus cash from time to time through our Investment Committee, which is comprised of one management director, Mr. Van Kirk, and two non-management directors, Mr. Cabillot and Mr. Swenson, who chairs the committee. Both Mr. Cabillot and Mr. Swenson are active investors with extensive portfolio management expertise. We leverage the experience of these committee members to make investment decisions for the investment of our surplus operating capital or borrowed funds. Additionally, many of our securities holdings include stocks of public companies that either Messrs. Swenson or Cabillot or both may own from time to time either individually or through the investment funds that they manage, or other companies whose boards they sit on. The Investment Committee approved each of the investments comprising the $2.7 million of marketable public equity securities held at March 31, 2023.

## Controls and procedures

As filed, 3,800 characters.

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer (the principal executive officer and principal financial officer, respectively) conducted an evaluation of the design and operation of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)). The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

In accordance with SEC rules, an evaluation was performed under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer of the effectiveness, as of March 31, 2023, of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). “Internal control over financial reporting” includes those policies and procedures that:

(1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and

(3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer’s assets that could have a material effect on the financial statements.

Based on that evaluation as of March 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are effective.

Internal Control Over Financial Reporting

During the three months ended March 31, 2023, there were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Inherent Limitations on the Effectiveness of Controls

In designing and evaluating our disclosure controls and procedures, our management recognized that any system of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

## Risk factors

As filed, 1,207 characters.

Our business, future financial condition and results of operations are subject to a number of factors, risks and uncertainties, which are disclosed in Item 1A, entitled “Risk Factors” in Part I of our Annual Report on Form 10-K for our fiscal year ended June 30, 2022, as well as any amendments thereto or additions and changes thereto contained in this quarterly report on Form 10-Q for the quarter ended March 31, 2023. Additional information regarding some of those risks and uncertainties is contained in the notes to the condensed consolidated financial statements included elsewhere in this report and in Item 2, entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in Part I of this report. The risks and uncertainties disclosed in our Form 10-K, our quarterly reports on Form 10-Q and other reports filed with the SEC are not necessarily all of the risks and uncertainties that may affect our business, financial condition and results of operations in the future.

There have been no material changes to the risk factors as disclosed in our annual report on Form 10-K for the fiscal year ended June 30, 2022, except as provided in any amendments thereto.

Filed May 4, 2023.
Source: SEC EDGAR, the filing index for accession 0001553350-23-000285. Last ingested by Listed: Oct 30, 2026, 16:16 ET. No prices; not investment advice.
